Balaji Amines Limited has notified the stock exchanges of the availability of the audio recording of its conference call held to discuss Q4FY26 financial results. The intimation was submitted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was communicated to both BSE Limited and the National Stock Exchange of India Limited on 18th May, 2026.

Conference Call Recording Details

The company stated that the audio recording of the conference call has been uploaded on its official website and is accessible to investors and stakeholders. The key details of the intimation are as follows:

Regulatory Compliance

The filing is in continuation of the company's earlier letter dated 13th May, 2026, which had intimated the schedule of the conference call to discuss Q4FY26 financial results. Balaji Amines confirmed that the transcript of the said call will be shared with the stock exchanges and also uploaded on the company's website in due course. The intimation was signed by Abhijeet Kothadiya, Company Secretary and Compliance Officer, on behalf of Balaji Amines Limited.

Balaji Amines Limited announced its audited financial results for the quarter and year ended March 31, 2026, approved by the Board of Directors at their meeting held on May 13, 2026. The specialty chemical company posted consolidated net profit of Rs 16,915.68 lakhs for the full year, compared to Rs 15,859.14 lakhs in the previous year, reflecting steady earnings growth. For Q4FY26, consolidated revenue from operations stood at ₹403 crore versus ₹361 crore in Q4FY25, while EBITDA came in at ₹102 crore against ₹68 crore in Q4FY25, with the EBITDA margin expanding to 25% from 19%. The board also recommended a final dividend of Rs 11 per equity share, representing 550% on the face value of Rs 2 per share, subject to shareholder approval at the 38th Annual General Meeting.

Consolidated Financial Performance

On a consolidated basis, revenue from operations for the full year stood at Rs 1,42,498.07 lakhs, up from Rs 1,39,708.44 lakhs in the previous year. Total income, including other income of Rs 2,880.67 lakhs, reached Rs 1,45,378.74 lakhs against Rs 1,43,028.76 lakhs previously. Profit before tax for the year came in at Rs 23,249.02 lakhs compared to Rs 21,321.94 lakhs in the prior year. For Q4FY26, consolidated profit before tax stood at Rs 8,586.03 lakhs against Rs 5,393.50 lakhs in Q4FY25. PAT for Q4FY26 was ₹65 crore as compared to ₹31 crore in Q3FY26, with diluted EPS for Q4FY26 at Rs 19.99 per equity share against Rs 9.49 in Q3FY26.

The following table summarises the consolidated financial results:

Standalone Financial Performance

On a standalone basis, revenue from operations for the full year was Rs 1,29,154.47 lakhs, compared to Rs 1,27,359.23 lakhs in the previous year. Standalone profit before tax for the year stood at Rs 22,740.40 lakhs against Rs 20,896.70 lakhs previously, while net profit for the year came in at Rs 16,552.83 lakhs versus Rs 15,621.27 lakhs. For Q4FY26, standalone revenue from operations was Rs 36,176.95 lakhs against Rs 32,155.87 lakhs in Q4FY25, with profit before tax of Rs 8,203.94 lakhs compared to Rs 5,303.44 lakhs. The company noted that on a standalone basis, it is a zero-debt company.

Volume Performance

Total consolidated volumes for Q4FY26 stood at 27,341 MT as against 25,871 MT in Q4FY25. The increase in revenue was attributed to commodity prices and consistent demand across key segments. The segment-wise volume breakdown for Q4FY26 is as follows:

Segment Performance

The consolidated segment reporting for the year ended March 31, 2026 shows that the Amines & Speciality Chemicals segment remained the dominant contributor, with segment revenue of Rs 1,41,568.99 lakhs for the full year compared to Rs 1,39,489.73 lakhs in the previous year. The Hotel Division recorded segment revenue of Rs 3,570.15 lakhs against Rs 3,320.08 lakhs previously. Segment profit before tax for the Amines & Speciality Chemicals division stood at Rs 22,007.51 lakhs for the year, up from Rs 20,275.13 lakhs, while the Hotel Division contributed Rs 917.90 lakhs against Rs 846.93 lakhs.

Balance Sheet and Cash Flow Highlights

The consolidated balance sheet as at March 31, 2026 reflects total assets of Rs 2,74,253.69 lakhs, up from Rs 2,25,205.91 lakhs as at March 31, 2025. Equity share capital remained unchanged at Rs 648.02 lakhs, while other equity stood at Rs 1,96,997.59 lakhs compared to Rs 1,83,857.79 lakhs in the prior year. On the standalone basis, total assets grew to Rs 2,02,366.67 lakhs from Rs 1,85,031.36 lakhs, with cash and cash equivalents rising to Rs 7,362.07 lakhs from Rs 3,849.24 lakhs. Consolidated net cash from operating activities for the year was Rs 18,403.76 lakhs, while net cash used in investing activities was Rs 34,357.29 lakhs, reflecting continued capital expenditure. Net cash from financing activities stood at Rs 8,456.72 lakhs on a consolidated basis.

New Projects and Expansion Plans

Balaji Amines outlined several projects under execution and commissioning. The DME Plant at Unit-IV is expected to be commissioned during the first quarter of FY 2026-27, with applications in the aerosol industry and as a replacement for LPG in industrial and commercial usage. N-Methyl Morpholine (NMM) with a capacity of 5,000 TPA is under execution and expected to be commissioned during FY 2026-27. An improved process-based Acetonitrile (ACN) plant is also under execution, targeted for commissioning during the second quarter of FY 2026-27. All projects are planned to be completed using internal accruals.

For subsidiary Balaji Speciality Chemicals Limited, an expansion of Rs 750 crore is underway in a phased manner, covering a wide range of products including Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN) 30% (Solution), Sodium Cyanide (NaCN) 100% (Pellets), Ethylene Diamine Tetra Acetic Acid (EDTA), and EDTA Disodium Salts (EDTA-2Na). The Industries, Energy, and Labour Department, Government of Maharashtra, has granted Mega Project status to this expansion under the Packaged Scheme of Incentives (PSI), 2019. At Unit-I, a brownfield project for EDA-based products with an additional reactor to manufacture value-added products such as DETA, TETA, PIP, AEEA, and AEP is expected to be commissioned during the first half of FY 2026-27. At Unit-II (the Greenfield Project at MIDC, Chincholi), erection and installation of equipment is in progress for manufacture of HCN, NaCN, EDTA, and EDTA-2Na, targeted for commissioning during Q4 of FY 2026-27.

Management Commentary

Commenting on the performance, Mr. D. Ram Reddy, Managing Director, stated that for the quarter and year ended March 31, 2026, the company demonstrated resilience in its operating performance despite a temporary external disruption during the month of March 2026. Production was briefly affected due to the geopolitical situation; however, the company was able to mitigate the impact through prudent inventory planning and uninterrupted availability of raw material. He noted that the fourth quarter performance strengthened the company's integrated manufacturing model and execution capabilities, enabling it to mitigate near-term volatility without materially affecting operations and customer servicing. Mr. Reddy added that the ramp-up of electronic-grade DMC, DMF, and other products is steadily strengthening the company's presence in higher-value segments. As the company enters the new financial year, its focus remains on improving utilization across all plants, enhancing operating leverage, and maintaining disciplined execution, backed by a resilient business plan, a growing specialty chemicals portfolio, and emerging export opportunities.

Dividend and Audit

The board has recommended a final dividend of Rs 11 per equity share (550% on face value of Rs 2 per share) for the year ended March 31, 2026, payable after shareholder approval at the 38th Annual General Meeting. The statutory auditors, M/s. M. Anandam & Co., Chartered Accountants, have issued unmodified audit opinions on both the standalone and consolidated financial results for the quarter and year ended March 31, 2026. The consolidated financial results include the results of subsidiary Balaji Speciality Chemicals Limited, prepared in accordance with Ind AS 110.

Regulatory Compliance

In compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Balaji Amines published newspaper advertisements containing an extract of its standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. The advertisements were published on May 14, 2026 in Business Standard (in English) and Tarun Bharat (in Marathi). The compliance filing was submitted to both BSE Limited and the National Stock Exchange of India Limited, and was signed by Abhijeet Kothadiya, Company Secretary & Compliance Officer.

Key Highlights

• Consolidated Net Profit for FY26: Rs 16,915.68 lakhs vs Rs 15,859.14 lakhs in FY25
• Consolidated Revenue from Operations for FY26: Rs 1,42,498.07 lakhs vs Rs 1,39,708.44 lakhs in FY25
• Q4FY26 Consolidated EBITDA: ₹102 crore vs ₹68 crore in Q4FY25; EBITDA margin expanded to 25% from 19%
• Q4FY26 Consolidated PAT: ₹65 crore vs ₹40 crore in Q4FY25
• Standalone Net Profit for FY26: Rs 16,552.83 lakhs vs Rs 15,621.27 lakhs in FY25; standalone company is zero-debt
• Final Dividend of Rs 11 per share (550% on face value of Rs 2) recommended
• Consolidated Total Assets as at March 31, 2026: Rs 2,74,253.69 lakhs
• BSCL Expansion: Rs 750 crore investment granted Mega Project status by Government of Maharashtra
• Unmodified audit opinion issued by M/s. M. Anandam & Co. on both standalone and consolidated results
• Regulatory Publication: Audited results published in Business Standard and Tarun Bharat on May 14, 2026 per SEBI Regulation 47